Karin E. Garvey

Labaton Sucharow (New York)
Lawyer (of Counsel)

With nearly two decades of litigation experience, Karin E. Garvey focuses on representing businesses and public pension funds in complex antitrust class actions. Prior to joining Labaton Sucharow, Karin practiced antitrust and general litigation at Kaye Scholer LLP, representing and counseling clients from a wide spectrum of industries including pharmaceuticals, cosmetics, building materials, film, finance, and private equity. Karin brings significant experience in managing complex, multijurisdictional cases from initial case development through resolution and appeal. She has prepared and defended company executives for deposition, hearing, and trial and has conducted similar examinations of her opponents. Karin also has significant experience working with experts—including economists, toxicologists, materials scientists, valuation experts, foreign law experts and appraisers, among others—developing reports and testimony, preparing for and defending depositions, as well as taking depositions of opponents’ experts. In addition, Karin has engaged in all phases of trial preparation and trial and has briefed and argued appeals. Karin obtained her J.D., cum laude, from Northwestern University School of Law, where she was a Note and Comment Editor for the Journal of Criminal Law and Criminology. She earned her A.B., cum laude, in Sociology from Harvard University. Karin is an Antitrust Section Member of the American Bar Association.

Linked author

Labaton Sucharow (New York)


314 Bulletin

Karin E. Garvey, Laura Shores The US District Court for the Eastern District of Pennsylvania holds the practice of a pharmaceutical company that does not require plaintiffs to meet any “threshold burden” in establishing a large reverse payment as unjustified in triggering analysis under antitrust rules of reason (Cephalon)


In re Modafinil Litigation Finds No “Threshold Burden” in Reverse Payment Suit* On Wednesday, January 28, in King Drug Company of Florence, Inc. v. Cephalon, Inc. (In re Modafinil), the US District Court for the Eastern District of Pennsylvania held that FTC v. Actavis, 133 S. Ct. 2223 (2013), (...)

Send a message